Actavis Divests Rights to Doryx to Mayne Pharma

February 12, 2015

Actavis will divest the US rights to its oral acne treatment brand Doryx and other assets related to the acne brand to Mayne Pharma, in a deal worth $50 million. Actavis currently holds the license for the distribution of Doryx in the US under a partnership between Warner Chilcott Plc, which was acquired by Actavis in 2013, and Mayne Pharma Group Ltd, an Australian specialty pharmaceutical. The company agreed to hand over the US rights for Doryx to Mayne, before the partnership ends this year. Actavis will be packaging, distributing, and promoting the brand until May 2, after which Mayne Pharma will establish its own US specialty brands unit for its commercial operations. 

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free